title: Oligonucleotide-based gene therapy for cardiovascular disease.
abstract: Gene therapy is emerging as a potential strategy for the treatment of cardiovascular disease such as restenosis after angioplasty, vascular bypass graft occlusion, transplant coronary vasculopathy, homozygous familial hypercholesterolemia and cystic fibrosis, for which no known effective therapy exists. Gene therapy requires efficient in vivo gene transfer technology. During the past decade, many gene transfer methods including viral transfer techniques have been developed, and some are being applied clinically in human gene therapy studies. Molecular biology and pathophysiology of the cardiovascular system have started to emerge, and the time is ripe for the introduction of gene therapy to the management of cardiovascular disorders. In this review, we have focused on the future potential of oligonucleotide-based gene therapy for the treatment of cardiovascular disease.
authors.affiliation: Department of Geriatric Medicine, Osaka University Medical School, Suita, Japan.
authors.forename: R
authors.initials: R
authors.lastname: Morishita
authors.forename: H
authors.initials: H
authors.lastname: Nakagami
authors.forename: Y
authors.initials: Y
authors.lastname: Taniyama
authors.forename: H
authors.initials: H
authors.lastname: Matsushita
authors.forename: K
authors.initials: K
authors.lastname: Yamamoto
authors.forename: N
authors.initials: N
authors.lastname: Tomita
authors.forename: A
authors.initials: A
authors.lastname: Moriguchi
authors.forename: K
authors.initials: K
authors.lastname: Matsumoto
authors.forename: J
authors.initials: J
authors.lastname: Higaki
authors.forename: T
authors.initials: T
authors.lastname: Ogihara
mesh_terms: D002318:Cardiovascular Diseases / Q000628:therapy*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*
chemical_list: D016376:Oligonucleotides, Antisense